SCHEMBL13157898

SCHEMBL13157898

O=C(c1ccc2ccccc2n1)N1C[C@@H](O)[C@H](N2CCN(Cc3ccc(Cl)cc3)CC2)C1

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ GRIN2B Q13224 2/20 0.59
▸ MEN1 O00255 1/20 0.52
▸ KMT2A Q03164 1/20 0.52
▸ MAPK1 P28482 1/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ NPC1 O15118 1/20 0.44
▸ TSHR P16473 1/20 0.44
▸ FAAH O00519 3/20 0.44
▸ MGLL Q99685 1/20 0.44
▸ SLC6A4 P31645 1/20 0.43
▸ CNR2 P34972 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.42
▸ GAA P10253 1/20 0.42
▸ TP53 P04637 1/20 0.41
▸ SIGMAR1 Q99720 1/20 0.40
▸ DRD4 P21917 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3109744 1.00 GRIN2B (0.59) GRIN2BMEN1KMT2AMAPK1RAB9A
SCHEMBL3089236 0.86 SMN1; SMN2 (0.54) GRIN2BMEN1KMT2AMAPK1RAB9A
SCHEMBL13157897 0.86 SMN1; SMN2 (0.54) GRIN2BMEN1KMT2AMAPK1RAB9A
SCHEMBL13157922 0.83 MCHR1 (0.55) MEN1KMT2ANPC1FAAHDRD4
SCHEMBL13182425 0.83 MCHR1 (0.55) MEN1KMT2ANPC1FAAHDRD4
SCHEMBL3098588 0.83 MCHR1 (0.55) MEN1KMT2ANPC1FAAHDRD4
SCHEMBL3098157 0.82 ACACB (0.44) FAAHTP53SIGMAR1DRD4
SCHEMBL13604077 0.82 ACACB (0.44) FAAHTP53SIGMAR1DRD4
SCHEMBL13158155 0.82 GPR183 (0.58) TP53
SCHEMBL13157665 0.82 GPR183 (0.58) TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399455-B2 Compounds useful as chemokine receptor antagonists MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-03-19 — — US disclosed
US-8399455-B2 Compounds useful as chemokine receptor antagonists MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-03-19 — — US disclosed
US-20100234356-A1 COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-09-16 — — US disclosed
US-20100234356-A1 COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-09-16 — — US disclosed
US-7635698-B2 Compounds useful as chemokine receptor antagonists MILLENNIUM PHARMACEUTICALS, INC. (US) 2009-12-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234356-A1 COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS ACKR3, CCR5, CXCR2 GRIN2B 1595/4885MEN1 2336/4885KMT2A 4425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback